Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12168915 | 0.87 | TDP1 (0.55) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL3451972 | 0.85 | ALDH1A1 (0.57) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL5511257 | 0.85 | TDP1 (0.54) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL22790395 | 0.84 | TDP1 (0.53) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL21119516 | 0.82 | PTGS1 (0.59) | TDP1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL22790344 | 0.81 | TDP1 (0.54) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL11527240 | 0.81 | L3MBTL1 (0.54) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL1179026 | 0.80 | NR1H4 (0.67) | NR1H4 | |
| SCHEMBL1283334 | 0.79 | ALDH1A1 (0.61) | L3MBTL1TDP1ALDH1A1TSHRLMNA | |
| SCHEMBL10394020 | 0.79 | ALDH1A1 (0.61) | L3MBTL1TDP1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108264506-B | Isoflavone derivative, preparation method and medical application thereof | 中国药科大学 | 2021-01-26 | — | — | CN | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| CN-106928247-A | Spiral shell oxindole compounds and its purposes as therapeutic agent | 泽农医药公司 | 2017-07-07 | — | — | CN | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| CN-103664973-B | Spiro-oxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-102256983-B | Spirooxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-05 | — | — | CN | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| CN-105218565-A | Spiral shell oxindole compounds and the purposes as therapeutical agent thereof | XENON PHARMACEUTICALS INC | 2016-01-06 | — | — | CN | disclosed |
| CN-105175433-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-12-23 | — | — | CN | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-20080114044-A1 | Compounds And Compositions As Ppar Modulators | EPPLE ROBERT | 2008-05-15 | — | — | US | disclosed |
| US-20080114044-A1 | Compounds And Compositions As Ppar Modulators | EPPLE ROBERT | 2008-05-15 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| EP-1745027-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| EP-1177176-B1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| WO-2005113519-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-01 | — | — | WO | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | L3MBTL1 2721/4885TDP1 2499/4885ALDH1A1 1020/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | L3MBTL1 3243/4885TDP1 2241/4885ALDH1A1 1580/4885 |
| US-20080114044-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | L3MBTL1 4402/4885TDP1 3465/4885ALDH1A1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.